Screening mammography
This article was originally published in The Gray Sheet
Executive Summary
Flaws cited by Cochrane Collaboration review in screening mammography methodology are insufficient to reject trial results entirely, updated U.S. Preventive Services Task Force recommendations state. Released Feb. 21, the updated guidelines advocate screening mammography in women over 40 every one to two years and in women over 50 every other year. Cochrane researchers Peter Gotzsche and Ole Olsen assert in the October 2001 issue of the Lancet that no reliable evidence exists to support screening mammography (1"The Gray Sheet" October 29, 2001, p. 20). NCI Director Andrew von Eschenbach and Donald Berry, MD, M.D. Anderson Cancer Center, Houston, are among those who will testify at a Feb. 28 Senate HELP/Public Health Subcommittee hearing on the issue...
You may also be interested in...
Breast Mammography Benefits Are Minimal For Women 40-49 – Annals Study
Mammography is not likely to reduce the number of breast cancer deaths by more than 20% in women ages 40-49, according to results from the Canadian National Breast Screening Study-1
Randomized Data To Support Screening Mammography Lacking - Horton
Reliable evidence from randomized trials is needed to support screening mammography programs, Richard Horton, MD, editor of the Lancet, concludes in an Oct. 20 commentary in the UK medical journal. "For a full independent overview to be completed, principal investigators of all component randomized trials will have to supply individual patient data," Horton asserts.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”